Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26840804 | 1.00 | SLC6A9 (0.85) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL427134 | 0.92 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL1052569 | 0.92 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL375237 | 0.91 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6823016 | 0.81 | SLC6A9 (0.80) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826926 | 0.80 | SLC6A9 (0.82) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6567625 | 0.80 | SLC6A9 (0.77) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6006325 | 0.79 | SLC6A9 (0.72) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826140 | 0.78 | SLC6A9 (0.75) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL7214281 | 0.77 | SLC6A9 (0.73) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885ALDH1A1 3127/4885CYP2D6 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.